Gain Therapeutics, Inc. (GANX) stock: key figures, P/E, revenue and dividend
Health Care · United States · ISIN US36269B1052
Gain Therapeutics, Inc. financials
| Fiscal year | 2025 |
|---|---|
| Operating income | -18.71 m USD |
| EBIT | -19.30 m USD |
| Net income | -20.16 m USD |
| Diluted EPS – continuing operations | -0.61 USD |
Full history since 2018, charts and your own formulas
This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.
About Gain Therapeutics, Inc.
Gain Therapeutics, Inc., a biotechnology company, develops novel small molecule therapeutics to treat diseases across various therapeutic areas in Switzerland, Spain, the United States, and Australia. The company's drug discovery platform Magellan discovers novel allosteric binding sites in a disease; identifies proprietary small molecules that bind these sites to modulate protein function; and treats the underlying cause of the disease. Its lead drug candidate is GT-02287, which is currently in a Phase 1b study for the treatment of Parkinson's disease with or without a GBA1 mutation. The company has various small molecule drug candidates, which are in the discovery, research, and preclinical stages for the treatment of dementia with Lewy bodies, Alzheimer's disease, and Gaucher's disease, lysosomal storage disorders, metabolic disorders, and solid tumors. Gain Therapeutics, Inc. was founded in 2017 and is based in Bethesda, Maryland.
More stocks
- RoboRobo Co. Ltd (215100.KQ)
- Ray Co. Ltd (228670.KQ)
- MOT Co.,Ltd. (413390.KQ)
- EUDA Health Holdings Ltd (EUDA)
- Mospec Semiconductor Corp (2434.TW)
- Man Zai Industrial Co Ltd (4543.TWO)
- Leef Brands Inc. (LEEEF)
- Coheris SA (COH.PA)
- Kuangli Photoelectric Technology Co Ltd (6431.TW)
- Ckd Bio (063160.KS)
- Endurance Gold Corp (EDG.V)
- Duck Yang Ind (024900.KS)
Not investment advice. All data without warranty, price as of 29.10.2026. Details in the risk notice.